Three analysts set AUD 3.64 target for Mesoblast stock, 82.91 percent above price

Published on 10/15/2026 at 21:12 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Mesoblast stock sits 39.88 percent below its AUD 3.31 high. It costs EUR 1.23 on October 15, 2026 at 9:05 p.m. CEST in after-hours trading.

Consensus target sets the frame

Three analysts supported an AUD 3.64 consensus target on September 15, 2026.
Mesoblast's annual general meeting is scheduled for November 10, 2026.
Mesoblast stock costs EUR 1.23 at Lang & Schwarz on October 15, 2026 at 9:05 p.m. CEST.
Mesoblast had an AUD 2.6 billion market capitalization on October 15, 2026.

MESO, AU000000MSB8, Illustration mit AI erstellt.

Three analysts supported an AUD 3.64 consensus target for Mesoblast (ISIN AU000000MSB8) on September 15, 2026, putting the target 82.91 percent above the AUD 1.99 share price cited by Simply Wall St. The target is the clearest dated valuation marker for Mesoblast stock in the current market picture.

Annual meeting set for November

Mesoblast's next scheduled corporate date is its annual general meeting on November 10, 2026, according to Simply Wall St. The meeting follows the October 12, 2026 notices listed on Mesoblast's investor-relations page and gives investors the next fixed date for company-level updates.

Price remains below the yearly high

On the ASX, Mesoblast's reported 52-week range was AUD 1.88 to AUD 3.31, with the AUD 1.99 share price 39.88 percent below the high and 5.85 percent above the low on October 15, 2026. The range places the stock nearer its yearly low than its yearly peak.

Mesoblast also trades on Nasdaq, where the latest quoted price was USD 13.98 on October 15, 2026 at 3:10 p.m. ET. The quote was 34.98 percent below the USD 21.50 yearly high and 7.13 percent above the USD 13.05 low, while the market capitalization was USD 1.8 billion.

Valuation and company scale

The AUD 3.64 consensus target compares with an AUD 2.6 billion market capitalization reported for Mesoblast on October 15, 2026. The target and the market value use the Australian share quotation, while the euro figure below reflects the German trading perspective.

Mesoblast develops regenerative medicine products and sells Ryoncil, its approved cell therapy for pediatric steroid-refractory acute graft-versus-host disease. Its pipeline also includes programs for chronic low back pain and other inflammatory conditions.

Price and investor perspective

The valuation target and the November 10 meeting provide two dated markers beyond the daily quote. The ASX range shows that the share price remains 39.88 percent below its AUD 3.31 high.

Mesoblast stock was trading at EUR 1.23 at Lang & Schwarz on October 15, 2026 at 9:05 p.m. CEST.

The further course of trading is shown by the continuously updated real-time quote of Mesoblast stock.